David Litzinger, Ph.D.

Dr. Litzinger has over 22 years of industry experience in drug discovery and development in the areas of compound physicochemical property assessment, preformulation, formulation, drug product manufacturing, and drug delivery. He has worked with multiple drug platforms, and with various routes of drug administration. His expertise is primarily in CMC, and he has extensive experience in other functional areas as well.

Dr. Litzinger played key roles in the identification of several developable medicines and their advancement to market, including products that reached commercialization (Kineret®, Sensipar®, and Myalept™) and several compounds and formulations that have entered clinical stage evaluation.

Most recently, Dr. Litzinger has been an independent discovery and development consultant to large pharmaceutical companies, small biotech companies, startups, and research institutions. He previously was Director, Biologics Product Development at Allergan, where he was responsible for formulation development of biologicals from discovery to commercialization, and oversaw drug product manufacturing development. Prior to Allergan, David was the Director of Pharmaceutical Sciences at Amylin. In this role he was responsible for preformulation, formulation, drug delivery, and external technology evaluation for peptide and protein therapeutics. David was an early employee of Ambrx, where he was the Director of Preclinical Sciences and successfully established and led several functions including pharmacology, pharmacokinetics, bioanalytics and toxicology and directed the preclinical development of modified proteins containing non-natural amino acids. Prior to Ambrx, David was a Research Scientist and Core Team Representative at Eli Lilly in Indianapolis, where he was responsible for evaluating small molecules during lead optimization, providing guidance to ensure pharmaceutical developability, providing preformulation support and physicochemical property assessment, and leading salt selection. Dr. Litzinger began his industry career at Amgen as a Research Scientist in pharmacology where he evaluated solubility and stability analogs, conjugates and fusion constructs as well as sustained release formulations of protein therapeutics.

Dr. Litzinger earned his Ph.D. in Biochemistry from the University of Tennessee and his B.S. in Biochemistry from Iowa State University.